NCT05803174

Brief Summary

To screen and identify sensitive biomarkers for high myopia via a robust, convenient, and cost-effective approach according to the association between high myopia and concentration of biomarkers in tear fluid, saliva and blood among adults and children.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
120

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Mar 2023

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

March 20, 2023

Completed
6 days until next milestone

First Submitted

Initial submission to the registry

March 26, 2023

Completed
12 days until next milestone

First Posted

Study publicly available on registry

April 7, 2023

Completed
2 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 31, 2023

Completed
2 months until next milestone

Study Completion

Last participant's last visit for all outcomes

July 31, 2023

Completed
Last Updated

April 7, 2023

Status Verified

March 1, 2023

Enrollment Period

2 months

First QC Date

March 26, 2023

Last Update Submit

March 26, 2023

Conditions

Keywords

biomarkers

Outcome Measures

Primary Outcomes (1)

  • Concentration of TNF-α in tear fluid, saliva and blood sample among emmetropic, low and moderate myopic, and high myopic groups

    TNF-α: Tumor necrosis factor is an adipokine and a cytokine.

    June 30, 2023

Secondary Outcomes (1)

  • Concentration of IL-1 in tear fluid, saliva and blood sample among emmetropic, low and moderate myopic, and high myopic groups

    June 30, 2023

Other Outcomes (5)

  • Concentration of IL-10 in tear fluid, saliva and blood sample among emmetropic, low and moderate myopic, and high myopic groups

    June 30, 2023

  • Concentration of IL-6 in tear fluid, saliva and blood sample among emmetropic, low and moderate myopic, and high myopic groups

    June 30, 2023

  • Concentration of TIMP in tear fluid, saliva and blood sample among emmetropic, low and moderate myopic, and high myopic groups

    June 30, 2023

  • +2 more other outcomes

Study Arms (3)

Emmetropic subjects

Spherical equivalent (Diopter, D) to be between -0.5 and +0.5 D

Diagnostic Test: blood sample

Low and moderate myopic subjects

Spherical equivalent (Diopter, D) to be less than -0.5 but over -6.0D

Diagnostic Test: blood sample

High myopic subjects

Spherical equivalent (Diopter, D) to be over or equal to -6.0D

Diagnostic Test: blood sample

Interventions

blood sampleDIAGNOSTIC_TEST

Blood collection Circulating serum concentrations of melatonin and dopamine were determined from fasting blood samples. Participants were required to fast from 10 pm the previous evening. A 5 mL serum blood sample was collected from the antecubital vein between 8.30 am and 10 am. Tear collection Tear samples were collected using Schirmer's strip without anesthesia between 8:30-10:00am. Tears were extracted in 200 μl of 1 X Phosphate Buffered Saline with 0.1% Tween-20 (PBST). Saliva collection Saliva samples were collected via the "passive drool" method with subjects in a seated position. Subjects were asked to rinse their mouth with water 10 minutes prior to saliva collection and to refrain from using lip makeup during the sampling period.

Also known as: saliva, tear fluid
Emmetropic subjectsHigh myopic subjectsLow and moderate myopic subjects

Eligibility Criteria

Age6 Years - 35 Years
Sexall
Healthy VolunteersYes
Age GroupsChild (0-17), Adult (18-64)
Sampling MethodNon-Probability Sample
Study Population

There are two levels of research, namely children and adults. Each level is divided into three groups of 20 subjects each. So about 120 subjects are anticipated in total. Taken into account the proportion of exclusion, 150 subjects are invited to recruitment.

You may qualify if:

  • Children aged 6-17
  • Removing flexible lenses for at least 1 week, flexible astigmatism and hard lenses for at least 3 weeks, orthokeratology lenses for at least 3 months;
  • Best corrected visual acuity of either eye were all ≥ 1.0;
  • The range of myopia in either eye was -15 D ≤ SE ≤ +1.0 D;
  • Astigmatism of either eye less than -5.0 D;
  • Anisometropia ≤ -1.5 D;
  • There was no active ocular inflammatory diseases; no obvious corneal cloud or macula, anormal corneal topography, and no tendency of keratoconus.
  • Intraocular pressure of either eye is of 10 to 21 mmHg;
  • On the basis of full understanding, children and their guardians sign the informed consent;
  • adults aged 18-35
  • Removing flexible lenses for at least 1 week, flexible astigmatism and hard lenses for at least 3 weeks, orthokeratology lenses for at least 3 months;
  • Best corrected visual acuity of either eye were all ≥ 1.0;
  • The range of myopia in either eye was -15 D ≤ SE ≤ +1.0 D;
  • Astigmatism of either eye less than -5.0 D;
  • Anisometropia ≤ -1.5 D;
  • +3 more criteria

You may not qualify if:

  • Amblyopia: best corrected visual acuity (BCVA) of either eye less than 1.0 for adults and children over 6 years old;
  • Active ocular inflammatory diseases, such as uveitis and other inflammatory diseases;
  • Secondary myopia, genetic disease or connective tissue- related myopia;
  • Moderate or severe ptosis;
  • Congenital cataract, glaucoma;
  • Other fundus diseases other than myopic related fundus lesions;
  • Intraocular or refractive surgery history;
  • The refractive medium is turbid, and it is impossible to take a clear fundus image; (9)Unable to cooperate with fundus image shooting and other examination;
  • (10)Do not receive cycloplegia or have contraindications; (11)Poor overall condition, unable to follow up for a long time; (12)The subject refuses to participate in the research; (13)Other cases in which the researcher judges that it is not suitable for participation in the study.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Beijing Tongren Hospital, Capital Medical University

Beijing, Beijing Municipality, 100073, China

Location

MeSH Terms

Interventions

Blood Specimen Collection

Intervention Hierarchy (Ancestors)

Specimen HandlingClinical Laboratory TechniquesDiagnostic Techniques and ProceduresDiagnosisPuncturesSurgical Procedures, OperativeInvestigative Techniques

Study Officials

  • Shi-Ming Li

    Beijing Tongren Hospital

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
CASE CONTROL
Time Perspective
CROSS SECTIONAL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

March 26, 2023

First Posted

April 7, 2023

Study Start

March 20, 2023

Primary Completion

May 31, 2023

Study Completion

July 31, 2023

Last Updated

April 7, 2023

Record last verified: 2023-03

Data Sharing

IPD Sharing
Will not share

Locations